Roivant to Present at Upcoming Investor Conferences
May 19 2022 - 4:30PM
Roivant Sciences (Nasdaq: ROIV) will participate in four upcoming
healthcare investor conferences:
- UBS Global Healthcare Conference in
New York City on Monday, May 23 at 9:15 a.m. EDT. CEO Matt Gline
will present.
- H.C. Wainwright Global Investment
Conference in Miami on Tuesday, May 24 at 8:30 a.m. EDT. CFO
Richard Pulik will participate in a fireside chat.
- Jefferies Healthcare Conference in
New York City on Wednesday, June 8 at 2:00 p.m. EDT. CEO Matt Gline
will participate in a fireside chat.
- Goldman Sachs Global Healthcare
Conference in Rancho Palos Verdes, CA on Tuesday, June 14 at 8:40
a.m. PDT / 11:40 a.m. EDT. CFO Richard Pulik and President and
Chief Investment Officer Mayukh Sukhatme will participate in a
fireside chat.
A live webcast of each presentation and fireside chat will be
available under “Events & Presentations” on the Investors
section of the Roivant website
at https://investor.roivant.com/news-events/events, and
archived recordings will be available after each presentation.
About Roivant SciencesRoivant's mission is to
improve the delivery of healthcare to patients by treating every
inefficiency as an opportunity. Roivant develops transformative
medicines faster by building technologies and developing talent in
creative ways, leveraging the Roivant platform to launch 'Vants' –
nimble and focused biopharmaceutical and health technology
companies. For more information, please
visit www.roivant.com.
Roivant Sciences Forward-Looking Statements
This press release contains forward-looking statements.
Statements in this press release may include statements that are
not historical facts and are considered forward-looking within the
meaning of Section 27A of the Securities Act of 1933, as amended
(the "Securities Act"), and Section 21E of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), which are usually
identified by the use of words such as "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intends," "may,"
"might," "plan," "possible," "potential," "predict," "project,"
"should," "would" and variations of such words or similar
expressions. The words may identify forward-looking statements, but
the absence of these words does not mean that a statement is not
forward-looking. We intend these forward-looking statements to be
covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and
Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to,
statements regarding our or our management team's expectations,
hopes, beliefs, intentions or strategies regarding the future, and
statements that are not historical facts, including statements
about the clinical and therapeutic potential of our product
candidates, the availability and success of topline results from
our ongoing clinical trials and any commercial potential of our
product candidates. In addition, any statements that refer to
projections, forecasts or other characterizations of future events
or circumstances, including any underlying assumptions, are
forward-looking statements.
Although we believe that our plans, intentions, expectations and
strategies as reflected in or suggested by those forward-looking
statements are reasonable, we can give no assurance that the plans,
intentions, expectations or strategies will be attained or
achieved. Furthermore, actual results may differ materially from
those described in the forward-looking statements and will be
affected by a number of risks, uncertainties and assumptions,
including, but not limited to, those risks set forth in the Risk
Factors section of our filings with the U.S. Securities and
Exchange Commission. Moreover, we operate in a very competitive and
rapidly changing environment in which new risks emerge from time to
time. These forward-looking statements are based upon the current
expectations and beliefs of our management as of the date of this
press release, and are subject to certain risks and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements. Except as required by
applicable law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
ContactsInvestorsRoivant Investor
Relationsir@roivant.com
MediaPaul DavisRoivant Sciencespaul.davis@roivant.com
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Dec 2024 to Jan 2025
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Jan 2024 to Jan 2025